Immunotherapy has made a great breakthrough in recent years, and antibody therapy is the core of this breakthrough. Traditional antibody therapies target cell membrane surface antigens (such as PD-1 and PD-L1) or soluble antigens. However, ideal tumor antigens (such as RAS, P53, WT1, etc.) are mainly intracellular, which is a limitation of antibody therapy, while TCR that identifies tumor antigens usually has a low affinity for the corresponding antigen, resulting in immune escape of tumor cells. T cell receptor (TCR) activates T cells to enhance cellular immunity by identifying specific major histocompatibility complexes (MHC) and the presented MHC-antigen-peptide (MAP).
The TCR-like antibody technology platform mainly replaces TCR with antibodies to screen out antibodies with much higher affinity and specificity than TCR, so as to effectively target intracellular antigen.
Advantages of TCR-mimic Antibody Platform
1.Biocytogen's unique HLA/RenMab mice combined with our high-throughput antibody screening platform enable a one-step process to obtain fully human antibodies that identify MAP, ensuring a high-affinity binding in vivo while rapidly obtaining fully human antibodies.
2.The antibodies selected through screening have better affinity and specificity than TCRs.
3.The in situ large-fragment replacement and modification in RenMab mice ensure the diversity of antibody sequences.
4.The antibody development cycle is shortened dramatically with high-throughput antibody discovery and sequence analysis on Beacon.
5.The fully antibody sequences obtained by TCR-like antibody technology platform provide more candidates for subsequent antibody-related drugs, CAR-T, TCR-T and other fields. It provides more intracellular targets for targeted clearance of specific abnormal cells such as tumor cells, infected cells and senescent cells. In addition, TCR-like blocking antibodies can also be screened for specific cells that are attacked by the autoimmune disease, so as to avoid damage to normal tissues.
TCR-mimic Antibody Development
AACR 2022: Generation of TCR-mimic fully human antibodies against HLA-antigen-peptide complexes using HLA transgenic RenMice
Biocytogen Enters Agreement with CtM Bio to Co-Develop TCR-Mimic Antibody based Multi-Specific T cell Engagers
Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy